Cargando…

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubino, Christopher M, Stulik, Lukas, Rouha, Harald, Visram, Zehra, Badarau, Adriana, Wart, Scott A Van, Ambrose, Paul G, Goodwin, Matthew M, Nagy, Eszter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252729/ http://dx.doi.org/10.1093/ofid/ofy210.1219

Ejemplares similares

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
por: Van Wart, Scott A, et al.
Publicado: (2018)

Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing monoclonal IgGs penetrating the epithelial lining fluid
por: Stulik, Lukas, et al.
Publicado: (2019)

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics
por: Parmar, Keyur R., et al.
Publicado: (2023)

ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
por: Mavroudis, Panteleimon D., et al.
Publicado: (2019)

Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies
por: Rouha, Harald, et al.
Publicado: (2017)

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
por: Ayyar, Vivaswath S., et al.
Publicado: (2022)

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258
por: Szijártó, Valéria, et al.
Publicado: (2017)

LPI commissioning meeting held on 13.09.1388
por: Madsen, J H B
Publicado: (1988)

Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
por: Magyarics, Zoltan, et al.
Publicado: (2019)

Serum and Lung Pharmacokinetics of ASN100, a Monoclonal Antibody Combination for the Prevention and Treatment of Staphylococcus aureus Pneumonia
por: Magyarics, Zoltan, et al.
Publicado: (2017)

1388. Seasonality of Microbiology of Combat-related Wound Infections in Afghanistan
por: Soderstrom, Matthew A, et al.
Publicado: (2022)

Five birds, one stone: Neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody
por: Rouha, Harald, et al.
Publicado: (2014)

Molecular mechanism of leukocidin GH–integrin CD11b/CD18 recognition and species specificity
por: Trstenjak, Nikolina, et al.
Publicado: (2020)

Influence of Ni(2+) on urease activity produced by biofilms of Arthrobacter oxydans 1388
por: Marinkova, Dessislava, et al.
Publicado: (2014)

1388. Characteristics of Non-Tuberculous Mycobacterial Infections in Hematopoietic Stem-Cell Transplant Patients
por: Gleeson, Shana E, et al.
Publicado: (2019)

A method for measurement of human asparagine synthetase (ASNS) activity and application to ASNS protein variants associated with ASNS deficiency
por: Chang, Mario C, et al.
Publicado: (2023)

Cj1388 Is a RidA Homolog and Is Required for Flagella Biosynthesis and/or Function in Campylobacter jejuni
por: Irons, Jessica, et al.
Publicado: (2019)

1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
por: Van Wart, Scott A, et al.
Publicado: (2021)

Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies
por: Janesch, Philipp, et al.
Publicado: (2018)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Asn(12) and Asn(278): Critical Residues for In Vitro Biological Activity of Reteplase
por: Mandi, Naganath, et al.
Publicado: (2010)

Evaluation of delay discounting as a transdiagnostic research domain criteria indicator in 1388 general community adults
por: Levitt, E. E., et al.
Publicado: (2023)

Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies
por: Badarau, Adriana, et al.
Publicado: (2016)

Essential Nucleoid Associated Protein mIHF (Rv1388) Controls Virulence and Housekeeping Genes in Mycobacterium tuberculosis
por: Odermatt, Nina T., et al.
Publicado: (2018)

1388. Epidemiology and Treatment Outcomes of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
por: Vivian Tsai, Y, et al.
Publicado: (2021)

ASN guidelines on P values
por: Verhoef, Hans, et al.
Publicado: (2022)

Hyper-truncated Asn355- and Asn391-glycans modulate the activity of neutrophil granule myeloperoxidase
por: Tjondro, Harry C., et al.
Publicado: (2020)

Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms
por: Caldwell, Jane C., et al.
Publicado: (2012)

1388. Patients´ perceptions on barriers that prevent and promote the use of telemedicine for HIV care in the public health system of Buenos Aires
por: Kierszenowicz, Tomas, et al.
Publicado: (2023)

1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
por: Tarbell, Evan D, et al.
Publicado: (2021)

2021 ASN Virtual Meeting Abstracts
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Draft Genome Sequence of Propionibacterium acnes subsp. elongatum Strain Asn12
por: McDowell, Andrew, et al.
Publicado: (2018)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Saccharomyces cerevisiae ASN1 and ASN2 are asparagine synthetase paralogs that have diverged in their ability to polymerize in response to nutrient stress
por: Noree, Chalongrat, et al.
Publicado: (2019)

1388. DTaP-containing combination vaccines use and adherence to the recommended infant-toddler vaccination series among privately insured children in the US
por: Loiacono, Matthew M, et al.
Publicado: (2020)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
por: Ferreira, Abigail, et al.
Publicado: (2021)

ASN Science Policy Fellows Advocate for Medical Research
por: Brown, Alison, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ah29i6nv9kkk3mtbfa5sma7e8